Could I double my money if I buy at this Darktrace share price?

The Darktrace share price has been volatile since its IPO. Yet, analysts expect the stock to double. Should I buy the shares for my own portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

The Darktrace (LSE: DARK) share price has been volatile since its initial public offering in April last year. The shares listed at 250p, rocketed up to 1,000p in September, and have fallen back to 373p as I write today.

However, City analysts have a consensus target price of 797p for Darktrace stock. That would be a 111% return, or a more than double my initial investment if I bought the shares today. Analysts aren’t always right, though. So, it’s important for me to form my own view before I buy any shares. Let’s take a closer look at the company.

The investment case

Darktrace operates in the cybersecurity industry. It’s area that I think will be in increasing demand as the world becomes more digital. This should, in theory, benefit Darktrace in the years ahead. Indeed, according to Fortune Business Insights, the cybersecurity market is expected to grow from $166bn in 2021 to $366bn in 2028.

On its website, Darktrace says it’s a world leader in autonomous artificial intelligence (AI) for cybersecurity. The signs look promising, too. For example, there are currently 6,531 customers using its cybersecurity products according to the recent trading update for the six months to 31 December (HY22). Customer numbers actually increased by 39.6% over the same period in 2020. Furthermore, Darktrace says its AI solutions are able to interrupt cyber attacks in seconds.

The recent trading update also showed strong growth in the business. Revenue increased 50% in the first six months of HY22. Guidance was also raised for its full-year revenue expectations to 30 June, and margins should increase, too. I can see why City analysts are expecting the share price to more than double if this growth continues.

Should I buy at this Darktrace share price?

However, Darktrace is still loss-making, which does make the investment riskier. The company isn’t expected to turn a profit for at least the next three years either. Based on a forward price-to-sales ratio though, the shares are valued on a multiple of seven. I consider this quite high. But if revenue continues to grow by double-digits, and the company maintains a 90% gross margin, then it isn’t unreasonable, in my view.  

My biggest issue today, though, is with the product. In fact, some customers have likened Darktrace’s products to “snake oil” due to the disconnect between the marketing of what its AI-driven solutions offer, and what it actually provides. This does make me question whether Darktrace’s AI is as good as it says it is. And although the recent trading was positive, it could be down to excellent marketing, rather than a world-leading cybersecurity product.

On this last point, Darktrace did say that churn had significantly improved over the half-year to 31 December. This does suggest that customers are sticking around and finding value in its products.

Nevertheless, there are too many risks on the product side for me to invest today, even though analysts expect the share price to double. Therefore, I think there’ll be considerable share price volatility ahead. Until Darktrace addresses the concerns over its product offering, I won’t be investing.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Dan Appleby has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Abstract bull climbing indicators on stock chart
Investing Articles

Could the Chancellor’s Leeds Reforms trigger a bull market for UK stocks?

More competitive lending and greater interest in shares could help kick start growth for UK businesses. But could it also…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

I think this AI stock could double before Palantir

Palantir stock is up almost 100% this year. As a result, it now sports a market cap of $350bn meaning…

Read more »

Elevated view over city of London skyline
Investing Articles

As the FTSE 100 hits an all-time high, is it time to reconsider the S&P 500?

Christopher Ruane explains why a surging FTSE 100 has not yet made him focus more on the potential of S&P…

Read more »

GSK scientist holding lab syringe
Investing Articles

The FTSE 100 sits at a record high. But some stocks still look dirt cheap!

The usually sluggish FTSE 100 is having a surprisingly good year. But our writer feels there are still potential bargains…

Read more »

Close-up of British bank notes
Investing Articles

With a £20k Stocks and Shares ISA, here are 3 ways an investor could target a £2k annual passive income

Our writer thinks there is more than one way to try and skin a cat when it comes to earning…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

Up 350% in 3 years but my favourite FTSE growth share is still on a low P/E of just 10!

Harvey Jones can't tear his eyes away from this former penny stock turned growth share superpower. But can it carry…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Up 83% in months, could Micron stock be the next Nvidia?

Chipmaker Micron Technology's stock price has surged by over 80% in just a few months. Could this be a possible…

Read more »

Tesla car at super charger station
US Stock

£1k invested in Tesla stock at the start of the year is currently worth…

Jon Smith reveals the performance of Tesla stock in 2025 and explains why he doesn't believe the move lower is…

Read more »